Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131142 | 1.00 | GRM5 (0.56) | GRM5HSD11B1EPHX2KCNH2ALDH1A1 | |
| SCHEMBL193072 | 0.86 | GRM5 (0.69) | GRM5HSD11B1EPHX2KCNH2ALDH1A1 | |
| SCHEMBL193071 | 0.86 | GRM5 (0.69) | GRM5HSD11B1EPHX2KCNH2ALDH1A1 | |
| SCHEMBL192547 | 0.84 | PPARA (0.58) | GRM5HSD11B1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL192546 | 0.84 | PPARA (0.58) | GRM5HSD11B1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL192618 | 0.83 | GPR119 (0.59) | GRM5HSD11B1ALDH1A1TSHRGPR119 | |
| SCHEMBL192619 | 0.83 | GPR119 (0.59) | GRM5HSD11B1ALDH1A1TSHRGPR119 | |
| SCHEMBL4142458 | 0.83 | GRM5 (0.47) | GRM5HSD11B1ALDH1A1TSHRNPC1 | |
| SCHEMBL4142455 | 0.83 | GRM5 (0.47) | GRM5HSD11B1ALDH1A1TSHRNPC1 | |
| SCHEMBL4138850 | 0.81 | GRM5 (0.52) | GRM5HSD11B1ALDH1A1TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-1896463-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006123249-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM3 | GRM5 1/4885HSD11B1 3098/4885EPHX2 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.